Navigation Links
Isis Pharmaceuticals to Present at the 2012 Citi Global Health Care Conference
Date:2/21/2012

CARLSBAD, Calif., Feb. 21, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Citi's 2012 Global Health Care Conference on Tuesday, February 28, 2012 at 2:00 p.m. ET at the Waldorf Astoria in New York City.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 26 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... -- The global peripheral I.V. catheter market accounted for ... to grow at a CAGR of 6.0% during 2016-2022. ... share in the global market between the two types ... hospital segment accounted for the highest share in the ... I.V. catheter market is witnessing high growth rate, due ...
(Date:1/23/2017)... , Jan. 23, 2017  HOPE BIOSCIENCES ... rights to develop and commercialize nuc -gemcitabine™ ... a Korean pharmaceutical company. nuc ... aptamer against surface nucleolin found on many cancer ... Unlike ADCs (antibody drug conjugates) or SMDCs (small ...
(Date:1/23/2017)... 23, 2017  Based on its recent analysis ... recognizes Ansell, a global leader in protection solutions, ... of the Year Award. Ansell,s comprehensive product portfolio, ... global footprint have placed it in a position ... The Company,s established product line and robust innovation ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... 23, 2017 , ... The Pharmacy and Medically Underserved Areas ... original co-sponsorship of nearly one-quarter of the U.S. House of Representatives. The Senate ... Drug Stores (NACDS) strongly backs the legislation. , “NACDS thanks for their leadership ...
(Date:1/24/2017)... Ariz. (PRWEB) , ... January 23, 2017 , ... ... recently analyzed statistics from 140 Buzzies users who entered metrics into the product’s ... earlier clinical data. The new data showed that within just 30 seconds of ...
(Date:1/23/2017)... ... , ... PKF O’Connor Davies , LLP, the nation’s 26th largest accounting ... Firm, will participate in the 40th Annual "Empire State Building Run Up" on Feb. ... steps, a vertical distance equal to about a fifth of a mile, to reach ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... Wooden and plastic balance boards have been ... and improve balance. Kumo Board is the first and only balance board to ... to be soft and rigid at the same time as well as skill-level adjustable for ...
(Date:1/23/2017)... ... 23, 2017 , ... METTLER TOLEDO has announced the availability ... Simple PAT Tools . , Crystallization is a common step used ... Chemists now spend more time developing better intermediate and final crystallization steps. ...
Breaking Medicine News(10 mins):